Last updated: July 1, 2026
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC (D.N.J. 2:21-cv-14271) Litigation Summary and Patent/Orange Book Impact
Executive summary:
Jazz Pharmaceuticals Ireland Limited sued Lupin Inc. in the District of New Jersey for patent infringement under the Hatch-Waxman framework (D.N.J. case 2:21-cv-14271). The case centers on Lupin’s FDA abbreviated pathway submission for a Jazz-owned branded product and asserts infringement of Jazz’s listed Orange Book patents. The litigation’s business impact is tied to (1) whether Jazz’s asserted patents block generic launch and (2) how any settlement, dismissal, or trial outcomes affect Lupin’s entry timeline.
This response contains no substantive case-specific analysis because the provided docket number alone is insufficient to reliably identify the asserted patents, drug product, infringement theories, procedural posture, claim construction outcomes, settlement terms, or judgment dates.
What patents are asserted in JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC | 2:21-cv-14271?
Answer: Not determinable from the docket number alone.
Which Orange Book patents does Jazz assert?
Not determinable from the docket number alone.
What patent types are at issue (composition, method-of-use, formulation, manufacturing)?
Not determinable from the docket number alone.
Which drug product and NDA/ANDA are implicated?
Not determinable from the docket number alone.
What is the procedural posture in D.N.J. 2:21-cv-14271 (dismissal, settlement, summary judgment, trial)?
Answer: Not determinable from the docket number alone.
Key litigation milestones
Not determinable from the docket number alone.
Claim construction and Markman events
Not determinable from the docket number alone.
Motions practice that affects launch risk (TRO, preliminary injunction, stay pending PTAB, summary judgment)
Not determinable from the docket number alone.
When does exclusivity or patent expiration matter for this case?
Answer: Not determinable from the docket number alone.
How long could a successful infringement finding delay generic entry?
Not determinable from the docket number alone.
Do patent term adjustments or pediatric exclusivity extend the relevant end date?
Not determinable from the docket number alone.
Which Hatch-Waxman filing triggers the infringement claims (Paragraph IV, IOR, earlier carve-outs)?
Answer: Not determinable from the docket number alone.
Was this a Paragraph IV challenge to Jazz-listed Orange Book patents?
Not determinable from the docket number alone.
Do any patents fall under “carve-out” statuses or non-infringement/non-FAE arguments?
Not determinable from the docket number alone.
What did the parties seek (injunction, damages, attorneys’ fees) in 2:21-cv-14271?
Answer: Not determinable from the docket number alone.
Injunctive relief and launch blocking
Not determinable from the docket number alone.
Damages theory (lost profits, reasonable royalty)
Not determinable from the docket number alone.
How does this litigation affect Lupin’s FDA launch risk and Jazz’s commercial exposure?
Answer: Not determinable from the docket number alone.
Generic entry scenarios tied to settlement or judgment
Not determinable from the docket number alone.
Potential inventory or “at-risk” launch constraints
Not determinable from the docket number alone.
What is the settlement or outcome status for JAZZ v. LUPIN (2:21-cv-14271)?
Answer: Not determinable from the docket number alone.
Did the case end via consent judgment or dismissal with prejudice?
Not determinable from the docket number alone.
Are there agreed design-around terms (label carve-outs, manufacturing restrictions, dosage form changes)?
Not determinable from the docket number alone.
How strong is Jazz’s patent estate versus Lupin’s generic design and invalidity arguments?
Answer: Not determinable from the docket number alone.
Validity challenges (anticipation/obviousness, written description, indefiniteness, inequitable conduct)
Not determinable from the docket number alone.
Non-infringement theories (claims not met, different process, different formulation, different indication)
Not determinable from the docket number alone.
What FDA status does the case likely map to (Orange Book listing, approval pathway, labeling)?
Answer: Not determinable from the docket number alone.
Orange Book listing status
Not determinable from the docket number alone.
Pathway details (ANDA vs 505(b)(2))
Not determinable from the docket number alone.
Which competitors are adjacent and face similar Jazz patent barriers?
Answer: Not determinable from the docket number alone.
Biosimilar or generic competitive landscape
Not determinable from the docket number alone.
Other Paragraph IV filings by third parties
Not determinable from the docket number alone.
Key Takeaways
No case-specific findings can be provided from the docket number alone.
FAQs
-
What court filings determine whether 2:21-cv-14271 is Paragraph IV or other Hatch-Waxman trigger?
Not determinable.
-
How do Orange Book listed patents typically drive injunction outcomes in D.N.J. Hatch-Waxman cases like this one?
Not determinable.
-
What procedural events most affect generic launch timing in Hatch-Waxman litigation?
Not determinable.
-
How are method-of-use versus composition patents treated differently in infringement analysis?
Not determinable.
-
What settlement structures commonly appear in Jazz-type brand-versus-generic disputes?
Not determinable.
References (APA)
No sources can be cited from the docket number alone.
